Leerink Partners reaffirmed their market perform rating on shares of Enhabit (NYSE:EHAB – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. Leerink Partners currently has a $8.00 target price on the stock, down from their prior target price of $8.50.
Enhabit Price Performance
Shares of NYSE EHAB opened at $7.56 on Tuesday. The firm has a market capitalization of $380.12 million, a PE ratio of -3.28 and a beta of 1.84. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.46 and a quick ratio of 1.46. Enhabit has a 1-year low of $6.85 and a 1-year high of $11.74. The business’s fifty day moving average price is $7.52 and its two-hundred day moving average price is $8.41.
Enhabit (NYSE:EHAB – Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The business had revenue of $253.60 million for the quarter, compared to analyst estimates of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same period last year, the business posted $0.03 earnings per share. On average, research analysts expect that Enhabit will post 0.25 EPS for the current year.
Institutional Inflows and Outflows
Enhabit Company Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
See Also
- Five stocks we like better than Enhabit
- Insider Trades May Not Tell You What You Think
- Tesla Investors Continue to Profit From the Trump Trade
- Profitably Trade Stocks at 52-Week Highs
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.